CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 281 enrolled
Drug / intervention
ALKS 3831drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02669758
NCT02669758Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia

Alkermes, Inc.·interventional·Posted Feb 1, 2016·Updated Jul 26, 2019

In Brief

A Phase 3 clinical trial evaluating ALKS 3831 for Schizophrenia. Completed, enrolled 281 participants across 31 sites in 4 countries.

Detailed Summary

The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesBulgaria, Serbia, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 1, 2016
Enrollment StartJan 20, 2016
Primary CompletionJun 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.4 years ago

Interventions

ALKS 3831drug

Tablets were administered for daily dosing